ICON, a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has acquired Timaq Medical Imaging, an European provider of advanced imaging services to pharmaceutical and biotech firms.
The acquisition of Timaq strengthens ICON’s existing medical imaging capabilities. ICON is a provider in the use of the core imaging laboratories and has conducted over 500 imaging trials on behalf of clients across the world.
Ted Gastineau, president of ICON Medical Imaging, said: “The acquisition of Timaq will complement our existing US operations by giving ICON a European base for our Medical Imaging operations. Alongside the immediate access to an experienced imaging team, Timaq’s strong links to leading medical institutions gives us access to important scientific expertise in the imaging field that will bring significant benefits to our clients.”
Gustav von Schulthess, co-founder of Timaq Medical Imaging, said: “We are excited to be joining ICON. Together we can enhance and expand the range of imaging services we offer our clients, while ICON’s global footprint will enable us to support even the largest multi-country imaging studies.
“We look forward to working closely with ICON’s imaging team to continue providing innovative imaging solutions that can help expedite clients’ drug development projects.”